Diabetic Peripheral Neuropathy Clinical Trial
Official title:
Prospective Study of Peripherla Neuropathy in Diabetic Type I
Diabetes mellitus type I is an increasing burden for more and younger children. Therapy
should avoid long-term complications as macrovascular diseases and diabetic nephropathy,
retinopathy and diabetic neuropathy (DN). There is considerable uncertainty about the
prevalence of DN due to a lack of large epidemiological studies and consensus on diagnostic
criteria. Nerve conduction velocity studies are regarded as the "gold standard" for
investigating neuropathies.
We plan a prospective study by investigating the peripheral nerve conduction velocity in a
population of diabetic children. At the same time-points, we will do a neurological
examination using the Young Score, a clinical score of peripheral neuropathy [10]. The
results obtained will be related to other long-term vascular complications (nephropathy,
retinopathy), glycaemic control, duration of diabetes, insulin dose regime, hours of
sports/week, and BMI
The number of newly diagnosed patients with diabetes mellitus type I increases every year,
with the patients becoming younger. The Austrian Diabetes Incidence Study Group demonstrated
a significant and constant increase in the incidence rate from 12.0 to 18.4/100,000 in
children and adolescents ≤15 years of age from 1999 to 2007 [7]. So, we are confronted with
more and more children and adolescents suffering from complications which determine
long-term outcome. Chronic disease and complications have an important impact on quality and
expectation of life and on health resources.
Among the long-term complications of diabetes, vascular complications including retinopathy,
nephropathy, neuropathy, and macrovascular disease are the most prevalent [2]. The main
therapeutic goal is to avoid these complications by early detection of clinical or, even
better, subclinical signs. For this reason, the International Society for Pediatric and
Adolescent Diabetes (ISPAD) periodically issues Clinical Practice Consensus Guidelines,
particularly for screening for vascular complications [2]. With regard to diabetic
neuropathy (DN) there is still uncertainty about the time frame, intensity and diagnostic
method of choice, despite it is a significant source of morbidity and mortality [3].
Additionally, there is considerable uncertainty about the prevalence of DN due to a lack of
large epidemiological studies and consensus on diagnostic criteria [4].
The American Academy of Neurology suggests a combination of objective and symptoms, signs
and electrophysiology provides the most accurate diagnosis of distal symmetric
polyneuropathy [5]. Nerve conduction studies are considered by many as the "gold standard"
for nerve damage and the most consistent indicator of (sub-)clinical neuropathy [6].
So far, several cross-sectional studies have been conducted on nerve conduction velocity in
diabetic children. The results in regard of prevalence are largely divergent. We found that
15 out of 39 patients (38.5%) had a pathological nerve conduction velocity. This result
neither correlated to a clinical symptom score (Young Score which consist of a Neurological
Deficiency Score, NDS and a Neuropathy Symptom Score, NSS) [10], nor to mean HbA1c, patients
age, duration of diabetes, body mass index, insulin regime, hours of sports or metabolic
testing results.
Only one long-term prospective study addressing the issue of the development of diabetic
neuropathy in a juvenile population was done so far [8]. To better understand the long term
development of diabetic neuropathy we plan to study the peripheral nerve conduction velocity
in a population of diabetic children from our outpatient clinic. At the same time, we will
do a neurological examination using the Young Score, a clinical score of peripheral
neuropathy [10].
The results obtained will be related to other long-term vascular complications (nephropathy,
retinopathy), glycaemic control, duration of diabetes, insulin dose regime, hours of
sports/week, and BMI
;
Observational Model: Cohort, Time Perspective: Prospective
Status | Clinical Trial | Phase | |
---|---|---|---|
Recruiting |
NCT04638556 -
Effect of Circulating lncRNAs on Type 2 Diabetic Peripheral Neuropathy
|
||
Completed |
NCT05580705 -
Effects of Vibration Therapy in Addition to Routine Physical Therapy in Patients With Diabetic Neuropathy
|
N/A | |
Terminated |
NCT01620775 -
MR(Magnetic Resonance) Imaging of Neurotransmitters in Chronic Pain
|
N/A | |
Completed |
NCT02127762 -
The Effect of Mindfulness Based Stress Reduction in Patients With Painful Diabetic Peripheral Neuropathy
|
N/A | |
Completed |
NCT00835757 -
Diffusion Tensor Imaging of Sural Nerves in Diabetic Peripheral Neuropathy
|
N/A | |
Recruiting |
NCT00553592 -
Double Blind RCT of Bicifadine SR in Outpatients With Chronic Neuropathic Pain Associated With Diabetes
|
Phase 2 | |
Recruiting |
NCT05863793 -
Clinical Study of Acupuncture in the Treatment of Diabetic Peripheral Neuropathy
|
N/A | |
Withdrawn |
NCT05041816 -
Peripheral Nerve Responses to Focal Vibration and Implications in Pain and Mobility for Patients With Diabetic Peripheral Neuropathy
|
N/A | |
Recruiting |
NCT06074562 -
A Study of LY3556050 in Adult Participants With Diabetic Peripheral Neuropathic Pain
|
Phase 2 | |
Recruiting |
NCT04457531 -
LiuWeiLuoBi Granule for the Treatment of Diabetic Peripheral Neuropathy
|
Early Phase 1 | |
Completed |
NCT02947828 -
Polyneuropathy in Diabetes Mellitus Type 2
|
||
Completed |
NCT02056431 -
Balancing Treatment Outcomes and Medication Burden Among Patients With Symptomatic Diabetic Peripheral Neuropathy
|
N/A | |
Completed |
NCT01681290 -
Safety and Efficacy of CBX129801 in Patients With Type 1 Diabetes
|
Phase 2 | |
Completed |
NCT01474772 -
Efficacy and Safety Study of Pregabalin in the Treatment of Pain on Walking in Patients With Diabetic Peripheral Neuropathy (DPN)
|
Phase 3 | |
Completed |
NCT01086150 -
Use of Topical Lidocaine to Reduce Pain in Patients With Diabetic Neuropathy
|
Phase 2/Phase 3 | |
Completed |
NCT03447756 -
Titration Study of ABX-1431
|
Phase 1 | |
Completed |
NCT04688671 -
Efficacy and Safety of ETX-018810 for the Treatment of Diabetic Peripheral Neuropathic Pain
|
Phase 2 | |
Completed |
NCT04984044 -
Effect of Vitamin D in Patients With Diabetic Peripheral Neuropathy to Alleviate Pain and Improvement of Symptoms
|
N/A | |
Completed |
NCT06130917 -
Effects of Multisystem Exercise on Balance, Postural Stability, Mobility and Pain in Patients With DPN.
|
N/A | |
Completed |
NCT01496365 -
Treatment of Neuropathic Pain Associated With Diabetic Peripheral Neuropathy
|
Phase 2 |